Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.

ABSTRACT:

Purpose

The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast cancer.

Patients and methods

Twenty-two patients with stage IV HER2/neu-positive breast cancer receiving trastuzumab therapy were vaccinated with an HER2/neu T-helper peptide-based vaccine. Toxicity was graded according to National Cancer Institute criteria, and antigen specific T-cell immunity was assessed by interferon gamma enzyme-linked immunosorbent spot assay. Data on progression-free and overall survival were collected.

Results

Concurrent trastuzumab and HER2/neu vacc

SUBMITTER: Disis ML 

PROVIDER: S-EPMC2754913 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature